In a significant turn of events, Novartis AG and Incyte Corporation have reached a settlement in their protracted legal dispute concerning unpaid royalties, just before the scheduled start of their trial. According to recent reports, the case, which was to be heard by a Manhattan federal judge, involved Novartis’s claim over $500 million in royalties related to their agreement to commercialize an Incyte-developed compound for blood cancer treatment.
The legal battle, spanning five years, centered around the financial arrangements between the two pharmaceutical giants. The details of the settlement have yet to be disclosed, and it remains to be seen what impact this resolution will have on the commercial strategies of both companies moving forward.
For more information on this development, the original article provides additional insights.